Valeo Foods Group Acquires Leading Italian Bakery Company Dal Colle
29.5.2024 13:05:00 EEST | Business Wire | Press release
Valeo Foods Group (“Valeo Foods” or “The Group”), one of Europe’s leading producers of quality sweets, treats and snacks, has completed the process to acquire assets of a renowned Italian producer of high-quality bakery products, Dal Colle.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240529721501/en/
Ronald Kers, CEO of Valeo Foods Group (Photo: Business Wire)
With a history and heritage dating back 120 years, Dal Colle produces a range of bakery products, sweet treats and snacks for every occasion including Pandori, Panettoni and Croissants. Its range of over 180 products is currently sold in over 35 countries around the world.
Dal Colle provides a highly complementary addition to Valeo’s expanding Italian platform and operations, built on its initial acquisition of Balconi in 2015 and the subsequent acquisitions of Val D’Enza in 2017 and IDP Pattini in 2023.
Ronald Kers, CEO of Valeo Foods Group, said: "Dal Colle is a fantastic addition to the Valeo Foods portfolio which already boasts many of Europe’s finest and most established brands, with deep heritage and connections with consumers. On a commercial level it diversifies and strengthens our product offering and completes our range of quality confectionary and sweet treats in this market, ranging from iconic sponge cakes to wafers and biscuits. It also adds considerable new manufacturing and logistical capabilities to our Italian platform, which will support our growth ambitions in Italy and across Europe. This is very consistent with our vision to position Valeo Foods as the undisputed European sweet treats champion.”
Alberto Alfieri, CEO of Valeo Foods Italy & President of Balconi Spa, said: “We have long admired Dal Colle who share our passion for delivering high-quality products to consumers and their heritage range and operational footprint are highly complementary to Valeo Foods Italy and the Balconi business. We very much look forward to welcoming close to 90 new colleagues to our team and work with them to accelerate the growth of our enlarged Italian business.”
Valeo Foods Group is one of Europe’s fastest growing food groups and one of Europe’s leading producers and purveyors of quality sweets, treats and snacks.
With revenues in excess of €1.5 billion, the Valeo Foods portfolio includes over 80 brands enjoyed by customers in over 106 countries around the world including Balconi, Carstens, Jacobs, Barrat, Fox’s Mints, Taveners, Poppets, Rowse Honey and Maple Crest. The Group employs over 4,500 people across 30 manufacturing facilities and offices in the UK, Italy, Germany, the Netherlands, Ireland, the Czech Republic and Canada. Valeo Foods Group is owned by leading global investment firm Bain Capital.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529721501/en/
Contact information
Media Enquiries on behalf of Valeo Foods Group:
Robert Brown, Associate Partner, Reputation Inc
rbrown@reputation-inc.com
+353 85 725 2626
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
